SalioGen’s CEO on the company’s ‘Gene Coding’ approach to genetic medicine and an oral presentation today at #ASGCT2024 for its Stargardt disease program

blonca9
May 7, 2024
1 min read

Jason Cole describes how Gene Coding can deliver large sequences to the genome without viral vectors or RNA guides, and describes how these benefits translate to the Stargardt program.

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

SalioGen’s CEO on the company’s ‘Gene Coding’ approach to genetic medicine and an oral presentation today at #ASGCT2024 for its Stargardt disease program

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight